Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1649

Dalmitamig

Home » Dalmitamig

Background of Dalmitamig

Dalmitamig (REGN7075), a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells (unlike other bsAbs that target CD3), facilitating T-cell activation through endogenous tumor antigens.

Specifications

Catalog Number:
KB-1649
Antibody Name:
Dalmitamig
Isotype:
Human IgG4
FC Muations:
CD28 HC: S228P/E233P/F234AV/L235Del/G236A/H435R/Y436F/L445P EGFR HC: S228P/E233P/F234AV/L235Del/G236A
Target:
EGFRxCD28
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Neil Howard Segal et al., A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.. JCO 42, 2503-2503(2024).
  2. WO2020198009 - EGFR x CD28 MULTISPECIFIC ANTIBODIES